Back
Johnson & Johnson 10K Form
Sell
45
JNJ
Johnson & Johnson
Last Price:
160.84
Seasonality Move:
2.65%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-07-25 | 10Q | JNJ/Johnson & Johnson Quarterly |
2024-05-01 | 10Q | JNJ/Johnson & Johnson Quarterly |
2024-02-16 | 10K | JNJ/Johnson & Johnson Annual |
2023-10-27 | 10Q | JNJ/Johnson & Johnson Quarterly |
2023-07-31 | 10Q | JNJ/Johnson & Johnson Quarterly |
2023-04-28 | 10Q | JNJ/Johnson & Johnson Quarterly |
Receive JNJ News And Ratings
See the #1 stock for the next 7 days that we like better than JNJ
JNJ Financial Statistics
Sales & Book Value
Annual Sales: | $85.16B |
---|---|
Cash Flow: | $5.71B |
Price / Cash Flow: | 20.43 |
Annual Sales: | $29.14 |
Price / Book: | 5.49 |
Profitability
EPS (TTM): | 6.05000 |
---|---|
Net Income (TTM): | $14.68B |
Gross Margin: | $58.61B |
Return on Equity: | 20.88% |
Return on Assets: | 8.49% |
Johnson & Johnson Earnings Forecast
Key Johnson & Johnson Financial Ratios
- The Gross Profit Margin over the past 40 years for JNJ is 68.82%.
- The Selling, General & Administrative Expenses for JNJ have been equal to 23.62% of Gross Profit Margin.
- The Research & Development expenses have been 17.71% of Revenue.
- The Interest Expense is 2.20% of Operating Income.
- The Net Earning history of JNJ is 41.28% of Total Revenues.
- Per Share Earnings over the last 40 years have been positive in 29 years.
Johnson & Johnson Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | S&P500 |
---|---|
Industry: | Pharmaceuticals |
Sector: | Health Care |
Current Symbol: | JNJ |
CUSIP: | 478160 |
Website: | jnj.com |
Debt
Debt-to-Equity Ratio: | 0.51 |
---|---|
Current Ratio: | 1.03 |
Quick Ratio: | 0.7 |
Price-to-Earnings
Trailing P/E Ratio: | 11.67 |
---|---|
Forward P/E Ratio: | 15.07 |
JNJ Technical Analysis vs Fundamental Analysis
Sell
45
Johnson & Johnson (JNJ)
is a Sell
Is Johnson & Johnson a Buy or a Sell?
-
Johnson & Johnson stock is rated a Sell
The current Johnson & Johnson [JNJ] share price is $160.09. The Score for JNJ is 45, which is 10% below its historic median score of 50, and infers higher risk than normal.